Loading clinical trials...
Loading clinical trials...
The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Neurogen Brain and Spine Institute
NCT07028333 · Mental Retardation
NCT06934850 · Mental Retardation
NCT06848959 · Cerebral Palsy, Mental Retardation, and more
NCT01403402 · Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), and more
NCT01031407 · Asperger's Disorder, Mental Retardation, and more
Neurogen brain and spine institute
Navi Mumbai, Maharashtra
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions